Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at On September 8, 2025, at 8:00 am ET, TOPLINE results from the RAP-219 phase trial were reported to resistant to focal seizure seizures.
Those interested in listening to live conference calls can use this webcast link or by dialing (800) 715-9871 in the United States or (646) 307-1963 for other locations and refer to conference ID 4762775. The company's website provides a 90-day “investor” section from the company's “Investor” section.
About therapies
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecular precision drugs for patients with neurological or mental illness. The company's founders have proposed groundbreaking discoveries related to the function of receptor-associated proteins (RAPs). Their findings form the basis of Rapport's RAP technology platform, which can adopt differentiated methods to generate precise small molecule product candidates and potentially overcome many of the limitations of conventional neurological drug discovery. The rapported precise neuroscience pipeline includes the company's main research drug, RAP-219, aims to achieve neuroanatomical specificity through RAP expressed only in discrete areas of the brain. The company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal episodes, bipolar mania and peripheral neuropathic pain in diabetes. Other preclinical and advanced discovery phase programs are also underway, including targeting chronic pain and hearing impairment.
touch
Julie DiCarlo
Communications and IR Director
Harmonious Therapy
[email protected]